Back to Top Amyloid Nomenclature 2020: Update and Recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Reference Materials

Amyloid Nomenclature 2020: Update and Recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee

key information

source: Amyloid: The International Journal of Experimental and Clinical Investigation

year: 2020

authors: Merrill D. Benson, Joel N. Buxbaum, David S. Eisenberg, Giampaolo Merlini, Maria J. M. Saraiva, Yoshiki Sekijima, Jean D. Sipe, Per Westermark

summary/abstract:

The ISA Nomenclature Committee met electronically before and directly after the XVII ISA International Symposium on Amyloidosis, which, unfortunately, had to be virtual in September 2020 due to the ongoing COVID-19 pandemic instead of a planned meeting in Tarragona in March. In addition to confirmation of basic nomenclature, several additional concepts were discussed, which are used in scientific amyloid literature. Among such concepts are cytotoxic oligomers, protofibrils, primary and secondary nucleation, seeding and cross-seeding, amyloid signature proteins, and amyloid plaques. 
 
Recommendations for their use are given. Definitions of amyloid and amyloidosis are confirmed. Possible novel human amyloid fibril proteins, appearing as ‘classical’ in vivo amyloid, were discussed. It was decided to include fibulin-like extracellular matrix protein 1 (amyloid protein: AEFEMP1), which appears as localised amyloid in portal veins.
 
The principles of the nomenclature have been given in earlier versions and for history. All amyloid fibril proteins are called protein A + the specific protein as a suffix, e.g. AL (L = immunoglobulin light chain) or ATTR (TTR = transthyretin). Further specification can be given after the protein name, e.g. ATTRwt or ATTRv (wt = wildtype and v = variant). If suitable, the specific mutation can replace v, e.g. ATTRV30M. Please observe that the Nomenclature Committee recommends the use of mature proteins in numbering of amino acid residues, i.e. without leader sequences.
 
organization: Indiana University School of Medicine, USA; The Scripps Research Institute, USA; University of California, USA; Foundation IRCCS Policlinico San Matteo, and University of Pavia, Italy; University of Porto, Portugal; Shinshu University School of Medicine, Japan; Boston University School of Medicine, USA; Uppsala University, Sweden

DOI: 10.1080/13506129.2020.1835263

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2025 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close